NCT07020221 - A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions

Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerSolid Tumor, AdultG12D Mutated KRAS

Interventions

DRUG

VS-7375

VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.

DRUG

Cetuximab

Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

DRUG

Carboplatin + Pemetrexed + Pembrolizumab

A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.

DRUG

Gemcitabine

A chemotherapy used for the treatment of several types of cancer including advanced or metastatic pancreatic ductal adenocarcinoma.

DRUG

Gemcitabine + Nab-paclitaxel

A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.

Trial Locations (5)

RECRUITING

SCRI Oncology Partners, Nashville

RECRUITING

Washington University School of Medicine, St Louis

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

Virginia Mason Medical Center, Seattle

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Verastem, Inc.

INDUSTRY